Cyclerion Therapeutics (NASDAQ:KRSA) Research Coverage Started at UBS Group

UBS Group began coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $55.00 price objective on the stock.

Separately, Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $55.00.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ KRSA opened at $31.91 on Friday. Cyclerion Therapeutics has a 12 month low of $7.19 and a 12 month high of $59.36. The firm has a market capitalization of $21.38 million, a price-to-earnings ratio of -2.75 and a beta of 1.75.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.